Kringle Pharma, Inc. (4884.T)
JPY 821.0
(0.37%)
JPY 821.0
(0.37%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.13 Billion JPY | 22.49% |
| 2022 | -2.75 Billion JPY | -28.95% |
| 2021 | -2.13 Billion JPY | -1.66% |
| 2020 | -2.1 Billion JPY | -1162.97% |
| 2019 | -166.47 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -2.34 Billion JPY | -9.59% |
| 2024 Q3 | -2.45 Billion JPY | 1.35% |
| 2024 Q2 | -2.48 Billion JPY | -6.33% |
| 2023 FY | -2.13 Billion JPY | 22.49% |
| 2023 Q1 | -2.59 Billion JPY | -3.56% |
| 2023 Q2 | -2.46 Billion JPY | 4.88% |
| 2023 Q4 | -2.13 Billion JPY | 10.31% |
| 2023 Q3 | -2.38 Billion JPY | 3.35% |
| 2022 Q4 | -2.5 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 387.642% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -88.412% |
| GNI Group Ltd. | -17.93 Billion JPY | 88.087% |
| Linical Co., Ltd. | -4.46 Billion JPY | 52.132% |
| Trans Genic Inc. | -221.16 Million JPY | -865.999% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 51.377% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 55.397% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 249.036% |
| AnGes, Inc. | -3.79 Billion JPY | 43.743% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -407.713% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 108.578% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -328.881% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -358.133% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 21.05% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -13.15% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -117.534% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 37.107% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -106.513% |
| Kidswell Bio Corporation | 343.58 Million JPY | 721.816% |
| PeptiDream Inc. | 3.29 Billion JPY | 164.9% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -119.669% |
| Ribomic Inc. | -2.09 Billion JPY | -1.75% |
| SanBio Company Limited | -3.78 Billion JPY | 43.624% |
| Healios K.K. | -2.19 Billion JPY | 2.443% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -126.117% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 18.583% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -50.769% |
| StemRIM | -8.41 Billion JPY | 74.596% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 54.382% |
| FunPep Company Limited | -1.79 Billion JPY | -19.132% |
| Stella Pharma Corporation | -1.11 Billion JPY | -90.86% |
| TMS Co., Ltd. | -3.44 Billion JPY | 38.012% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 61.544% |
| Cuorips Inc. | -5.56 Billion JPY | 61.581% |
| K Pharma,Inc. | -3.26 Billion JPY | 34.592% |
| Takara Bio Inc. | -32.2 Billion JPY | 93.366% |
| ReproCELL Incorporated | -2.93 Billion JPY | 27.307% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -223.24% |
| StemCell Institute Inc. | -2.83 Billion JPY | 24.685% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -3.395% |
| CellSeed Inc. | -2.01 Billion JPY | -6.185% |